MA50359A - Anticorps anti-cd38 et procédés d'utilisation - Google Patents

Anticorps anti-cd38 et procédés d'utilisation

Info

Publication number: MA50359A
Authority: MA; Morocco
Prior art keywords: antibodies; methods
Prior art date: 2017-10-10

Application number

MA050359A

Other languages

English (en)

Inventor

Béatrice Cameron

Tarik Dabdoubi

Cendrine Lemoine

Gary Nabel

Catherine Prades

Edward Seung

Ronnie Wei

Lan Wu

Ling Xu

Zhi-Yong Yang

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-10

Filing date

2018-10-09

Publication date

2020-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63963620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-10-09 Application filed by Sanofi Sa filed Critical Sanofi Sa

2020-08-19 Publication of MA50359A publication Critical patent/MA50359A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA050359A 2017-10-10 2018-10-09 Anticorps anti-cd38 et procédés d'utilisation MA50359A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201762570655P	2017-10-10	2017-10-10
US201762570660P	2017-10-11	2017-10-11
US201862676221P	2018-05-24	2018-05-24
EP18187186		2018-08-03

Publications (1)

Publication Number	Publication Date
MA50359A true MA50359A (fr)	2020-08-19

Family

ID=63963620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050359A MA50359A (fr)	2017-10-10	2018-10-09	Anticorps anti-cd38 et procédés d'utilisation

Country Status (20)

Country	Link
US (3)	US11186649B2 (fr)
EP (2)	EP4249068A3 (fr)
JP (4)	JP7036909B2 (fr)
KR (1)	KR20200061402A (fr)
CN (4)	CN120058938A (fr)
AR (1)	AR116718A1 (fr)
AU (1)	AU2018348093A1 (fr)
BR (1)	BR112020007002A2 (fr)
CA (1)	CA3078800A1 (fr)
ES (1)	ES2986579T3 (fr)
IL (1)	IL273871A (fr)
MA (1)	MA50359A (fr)
MX (1)	MX2020004129A (fr)
MY (1)	MY199781A (fr)
PH (1)	PH12020550408A1 (fr)
PY (1)	PY1888702A (fr)
SG (1)	SG11202003212PA (fr)
TW (4)	TW202430563A (fr)
UY (1)	UY37928A (fr)
WO (1)	WO2019074973A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1914242A1 (fr) *	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
TWI743461B (zh) *	2011-03-28	2021-10-21	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
KR102211837B1 (ko)	2013-01-14	2021-02-03	젠코어 인코포레이티드	신규한 이형이량체 단백질
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (fr)	2014-11-26	2017-10-04	Xencor, Inc.	Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
PE20171324A1 (es)	2014-11-26	2017-09-11	Xencor Inc	Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
CN120988137A (zh) *	2015-01-23	2025-11-21	赛诺菲	抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
RS62437B1 (sr)	2015-10-25	2021-11-30	Sanofi Sa	Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CA3020633A1 (fr)	2016-04-13	2017-10-19	Sanofi	Proteines de liaison trispecifiques et/ou trivalentes
LT3443006T (lt)	2016-04-13	2023-10-25	Sanofi	Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai
CN109715663B (zh)	2016-06-28	2022-11-25	Xencor股份有限公司	结合生长抑素受体2的异源二聚抗体
IL317134A (en)	2016-12-21	2025-01-01	Teneobio Inc	An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
KR20250007003A (ko)	2017-06-20	2025-01-13	테네오바이오, 인코포레이티드	항-bcma 중쇄-단독 항체
BR112020007002A2 (pt) *	2017-10-10	2020-11-17	Sanofi	anticorpos anti-cd38 e métodos de uso
JP2021502100A (ja)	2017-11-08	2021-01-28	ゼンコアインコーポレイテッド	新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
CA3096052A1 (fr)	2018-04-04	2019-10-10	Xencor, Inc.	Anticorps heterodimeres qui se lient a la proteine d'activation des fibroblastes
CN112585165B8 (zh)	2018-04-25	2025-02-14	普罗米修斯生物科学公司	优化的抗tl1a抗体
JP7462621B2 (ja) *	2018-10-09	2024-04-05	サノフイ	三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
WO2020206330A1 (fr)	2019-04-05	2020-10-08	Teneobio, Inc.	Anticorps à chaîne lourde se liant à psma
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof
EP3953388A1 (fr) *	2019-04-09	2022-02-16	Sanofi	Protéines de liaison trispécifiques, procédés et utilisations connexes
AU2020299600A1 (en)	2019-07-03	2022-01-06	Crystal Bioscience Inc.	Anti-CD38 antibody and methods of use thereof
AU2020337999A1 (en) *	2019-08-30	2022-03-24	Dragonfly Therapeutics, Inc.	Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind HER2, NKG2D, and CD16 for cancer treatment
NZ787680A (en)	2019-10-24	2026-02-27	Cedars Sinai Medical Center	Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2021080649A1 (fr)	2019-10-25	2021-04-29	Sanofi	Procédés d'analyse du mésappariement de chaîne dans des protéines de liaison multispécifiques
CN112876563B (zh) *	2019-11-29	2022-08-16	康诺亚生物医药科技（成都）有限公司	药物组合物及其制备方法和应用
IL297601A (en) *	2020-04-29	2022-12-01	Teneobio Inc	Multispecific heavy chain antibodies with modified heavy chain constant regions
TW202330622A (zh) *	2020-04-29	2023-08-01	美商泰尼歐生物公司	具有經修飾重鏈恆定區之多特異性重鏈抗體
WO2021231976A1 (fr)	2020-05-14	2021-11-18	Xencor, Inc.	Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
CA3192204A1 (fr) *	2020-08-19	2022-02-24	Xencor, Inc.	Anticorps anti-cd28 et/ou compositions anti-b7h3
MX2023003214A (es)	2020-09-18	2023-05-24	Regeneron Pharma	Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
US12144827B2 (en)	2021-02-25	2024-11-19	Lyell Immunopharma, Inc.	ROR1 targeting chimeric antigen receptor
US11739144B2 (en)	2021-03-09	2023-08-29	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (fr)	2021-03-10	2024-01-17	Xencor, Inc.	Anticorps hétérodimères qui se lient au cd3 et au gpc3
WO2023284806A1 (fr) *	2021-07-14	2023-01-19	江苏恒瑞医药股份有限公司	Molécule de liaison à l'antigène qui se lie spécifiquement à cd38, bcma et cd3 et ses utilisations médicales
US20250277051A1 (en) *	2021-08-02	2025-09-04	Hangzhou Unogen Biotech, Ltd	Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
EP4388000A1 (fr) *	2021-08-20	2024-06-26	Novartis AG	Procédés de fabrication de cellules exprimant un récepteur antigénique chimérique
US12365743B2 (en)	2022-02-23	2025-07-22	Xencor, Inc.	Anti-CD28 x anti-PSMA antibodies
EP4540284A2 (fr)	2022-06-17	2025-04-23	Apogee Therapeutics, Inc.	Anticorps se liant à l'interleukine 13 et méthodes d'utilisation
CN119487071A (zh) *	2022-06-24	2025-02-18	北京可瑞生物科技有限公司	基于t细胞受体的双特异性多肽分子及其用途
WO2024206439A2 (fr) *	2023-03-28	2024-10-03	Nkarta, Inc.	Anticorps et récepteurs antigéniques chimériques spécifiques pour cd38
WO2025027003A1 (fr)	2023-07-31	2025-02-06	Sanofi	Méthodes et utilisations pour des activateurs de lymphocytes t anti-cd38 dans le traitement de lymphomes t périphériques
WO2025209594A1 (fr) *	2024-04-06	2025-10-09	华深智药生物科技(苏州)有限公司	Anticorps anti-gucy2c et utilisation d'anticorps multi-spécifique
TW202602939A (zh) *	2024-04-06	2026-01-16	大陸商華深智藥生物科技（蘇州）有限公司	一種多特異性抗體t細胞銜接器
WO2026019667A1 (fr) *	2024-07-17	2026-01-22	Jn Biosciences Llc	Anticorps trispécifiques pour l'activation de cellules immunitaires

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3850542T2 (de)	1987-09-23	1994-11-24	Bristol Myers Squibb Co	Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
ATE375365T1 (de)	1998-04-02	2007-10-15	Genentech Inc	Antikörper varianten und fragmente davon
CN1294148C (zh)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	环状单链三特异抗体
WO2004106375A1 (fr) *	2003-05-30	2004-12-09	Merus Biopharmaceuticals B.V. I.O.	Banque de fab pour la preparation de fab anti-vegf et antirabique
NZ544924A (en) *	2003-06-27	2009-03-31	Biogen Idec Inc	Modified binding molecules comprising connecting peptides
US9200061B2 (en) *	2004-02-06	2015-12-01	Morpho Sys AG	Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
KR20140066259A (ko) *	2004-02-06	2014-05-30	모르포시스 아게	항-ｃｄ３８ 인간 항체 및 그의 용도
CN100376599C (zh)	2004-04-01	2008-03-26	北京安波特基因工程技术有限公司	基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
JP5225069B2 (ja) *	2005-03-23	2013-07-03	ゲンマブエー／エス	多発性骨髄腫の治療のためのｃｄ３８に対する抗体
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP1914242A1 (fr) *	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2050764A1 (fr)	2007-10-15	2009-04-22	sanofi-aventis	Nouveau format d'anticorps bispécifique polyvalent
CA2726087A1 (fr)	2008-06-03	2009-12-10	Tariq Ghayur	Immunoglobulines a deux domaines variables et leurs utilisations
CA2774636C (fr)	2009-09-25	2019-05-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps neutralisants diriges contre le vih-1 et utilisation associee
SMT202000031T1 (it)	2010-06-09	2020-03-13	Genmab As	Anticorpi contro cd38 umano
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
TWI743461B (zh)	2011-03-28	2021-10-21	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (fr)	2011-05-09	2012-11-15	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Anticorps neutralisants anti-vih-1 et leur utilisation
CN103797029B (zh)	2011-05-17	2016-08-17	洛克菲勒大学	人类免疫缺陷病毒中和抗体及其使用方法
BR112014010823B1 (pt)	2011-11-07	2021-02-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
EP2788376B1 (fr)	2011-12-08	2018-10-03	The United States of America, as represented by The Secretary, Department of Health and Human Services	Anticorps neutralisants dirigés contre le vih-1 et leur utilisation
HUE033245T2 (hu) *	2011-12-19	2017-11-28	Synimmune Gmbh	Bispecifikus ellenanyag molekula
WO2013163427A1 (fr)	2012-04-25	2013-10-31	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Anticorps pour traiter les infections par le vih-1
WO2014089152A1 (fr)	2012-12-04	2014-06-12	University Of Maryland, Baltimore	Anticorps liant la protéine env du vih-1, protéines de fusion et leurs méthodes d'utilisation
US20140213772A1 (en)	2012-12-28	2014-07-31	Abbvie, Inc.	Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) *	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
WO2014116846A2 (fr)	2013-01-23	2014-07-31	Abbvie, Inc.	Procédés et compositions pour moduler une réponse immunitaire
CN105209491A (zh)	2013-03-15	2015-12-30	艾伯维公司	针对TNFα的双重特异性结合蛋白
JP2016538275A (ja) *	2013-11-04	2016-12-08	グレンマークファーマシューティカルズ，エセ．アー．	Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
EP3699195A3 (fr)	2014-03-28	2020-11-04	Xencor, Inc.	Anticorps bispécifiques se liant à cd38 et cd3
CN106687584B (zh)	2014-09-04	2021-08-13	干细胞技术公司	用于t细胞或nk细胞活化和扩增的可溶性抗体复合物
JP6180663B2 (ja) *	2014-12-23	2017-08-16	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｔｉｇｉｔに対する抗体
CN120988137A (zh)	2015-01-23	2025-11-21	赛诺菲	抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
WO2016196740A1 (fr)	2015-06-02	2016-12-08	The Rockefeller University	Anticorps tri-spécifiques pour traitement anti-vih
RS62437B1 (sr)	2015-10-25	2021-11-30	Sanofi Sa	Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CN105837688B (zh) *	2015-11-20	2019-02-26	北京大学深圳研究生院	单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
CA3020633A1 (fr)	2016-04-13	2017-10-19	Sanofi	Proteines de liaison trispecifiques et/ou trivalentes
WO2018120842A1 (fr)	2016-12-30	2018-07-05	上海欣百诺生物科技有限公司	Molécule bifonctionnelle et son utilisation
WO2018151841A1 (fr)	2017-02-17	2018-08-23	Sanofi	Molécules de liaison multispécifiques ayant une spécificité vis-à-vis du dystroglycane et de la laminine-2
BR112020007002A2 (pt)	2017-10-10	2020-11-17	Sanofi	anticorpos anti-cd38 e métodos de uso
JP7462621B2 (ja)	2018-10-09	2024-04-05	サノフイ	三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof

2018
- 2018-10-09 BR BR112020007002-5A patent/BR112020007002A2/pt not_active IP Right Cessation
- 2018-10-09 MA MA050359A patent/MA50359A/fr unknown
- 2018-10-09 US US16/155,807 patent/US11186649B2/en active Active
- 2018-10-09 AU AU2018348093A patent/AU2018348093A1/en not_active Abandoned
- 2018-10-09 CN CN202510116993.7A patent/CN120058938A/zh active Pending
- 2018-10-09 ES ES18792827T patent/ES2986579T3/es active Active
- 2018-10-09 SG SG11202003212PA patent/SG11202003212PA/en unknown
- 2018-10-09 MX MX2020004129A patent/MX2020004129A/es unknown
- 2018-10-09 CN CN202311405579.5A patent/CN117964758A/zh active Pending
- 2018-10-09 EP EP23173927.7A patent/EP4249068A3/fr active Pending
- 2018-10-09 CA CA3078800A patent/CA3078800A1/fr active Pending
- 2018-10-09 KR KR1020207013073A patent/KR20200061402A/ko active Pending
- 2018-10-09 MY MYPI2020001741A patent/MY199781A/en unknown
- 2018-10-09 CN CN201880079045.9A patent/CN111788225B/zh active Active
- 2018-10-09 WO PCT/US2018/055084 patent/WO2019074973A2/fr not_active Ceased
- 2018-10-09 CN CN202510123093.5A patent/CN120058939A/zh active Pending
- 2018-10-09 EP EP18792827.0A patent/EP3694882B1/fr active Active
- 2018-10-09 JP JP2020519704A patent/JP7036909B2/ja active Active
- 2018-10-10 UY UY0001037928A patent/UY37928A/es not_active Application Discontinuation
- 2018-10-10 PY PY201801888702A patent/PY1888702A/es unknown
- 2018-10-11 TW TW112139669A patent/TW202430563A/zh unknown
- 2018-10-11 TW TW107135898A patent/TWI821202B/zh not_active IP Right Cessation
- 2018-10-11 TW TW112124284A patent/TW202342544A/zh unknown
- 2018-10-11 TW TW112139671A patent/TW202432580A/zh unknown
2019
- 2019-10-08 AR ARP190102858A patent/AR116718A1/es unknown
2020
- 2020-04-07 IL IL273871A patent/IL273871A/en unknown
- 2020-04-10 PH PH12020550408A patent/PH12020550408A1/en unknown
2021
- 2021-10-15 US US17/503,038 patent/US11365261B2/en active Active
2022
- 2022-03-02 JP JP2022031377A patent/JP7387780B2/ja active Active
- 2022-05-05 US US17/737,814 patent/US20220275102A1/en active Pending
2023
- 2023-11-14 JP JP2023193393A patent/JP7733711B2/ja active Active
2025
- 2025-08-20 JP JP2025136683A patent/JP2025175288A/ja active Pending

Also Published As

Publication number	Publication date
TW202430563A (zh)	2024-08-01
US20190106504A1 (en)	2019-04-11
CN111788225B (zh)	2025-02-18
JP2025175288A (ja)	2025-12-01
WO2019074973A3 (fr)	2019-06-13
SG11202003212PA (en)	2020-05-28
JP2022071087A (ja)	2022-05-13
TW201930338A (zh)	2019-08-01
TW202432580A (zh)	2024-08-16
JP7036909B2 (ja)	2022-03-15
US20220275102A1 (en)	2022-09-01
RU2020115450A (ru)	2021-11-15
US20220041746A1 (en)	2022-02-10
PH12020550408A1 (en)	2021-04-12
US11186649B2 (en)	2021-11-30
CN120058938A (zh)	2025-05-30
EP4249068A3 (fr)	2023-11-22
AR116718A1 (es)	2021-06-09
KR20200061402A (ko)	2020-06-02
CN120058939A (zh)	2025-05-30
IL273871A (en)	2020-05-31
EP3694882B1 (fr)	2024-06-19
EP4249068A2 (fr)	2023-09-27
EP3694882A2 (fr)	2020-08-19
US11365261B2 (en)	2022-06-21
CA3078800A1 (fr)	2019-04-18
WO2019074973A2 (fr)	2019-04-18
CN117964758A (zh)	2024-05-03
JP2024020377A (ja)	2024-02-14
MY199781A (en)	2023-11-23
TW202342544A (zh)	2023-11-01
JP2020536543A (ja)	2020-12-17
AU2018348093A1 (en)	2020-05-28
TWI821202B (zh)	2023-11-11
UY37928A (es)	2019-05-31
JP7387780B2 (ja)	2023-11-28
BR112020007002A2 (pt)	2020-11-17
ES2986579T3 (es)	2024-11-12
MX2020004129A (es)	2020-08-20
CN111788225A (zh)	2020-10-16
PY1888702A (es)	2020-02-07
JP7733711B2 (ja)	2025-09-03

Publication	Publication Date	Title
MA50359A (fr)	2020-08-19	Anticorps anti-cd38 et procédés d'utilisation
MA50948A (fr)	2020-10-14	Anticorps et procédés d'utilisation de ceux-ci
MA50956A (fr)	2020-10-14	Anticorps anti-cd137 et procédés d'utilisation correspondants
MA43018A (fr)	2021-06-02	Anticorps anti-pd1 et procédés d'utilisation
FR24C1050I1 (fr)	2025-01-17	Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
FR24C1044I2 (fr)	2025-05-23	Anticorps anti-c5 et leurs procédés d'utilisation
MA52753A (fr)	2021-04-21	Anticorps anti-sirpa et leurs procédés d'utilisation
EP3634430A4 (fr)	2021-04-14	Agents multibiotiques et procédés d'utilisation de ceux-ci
MA42043A (fr)	2018-03-14	Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3797123A4 (fr)	2022-03-02	Anticorps anti-ox40 et procédés d'utilisation
EP3612198A4 (fr)	2021-01-13	Bactéries commensales modifiées et procédés d'utilisation
MA53355A (fr)	2022-03-16	Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3710589A4 (fr)	2021-11-10	Anticorps anti-c1s et procédés d'utilisation
MA42925A (fr)	2018-08-01	Anticorps anti-tigit et méthodes d'utilisation
MA45671A (fr)	2021-04-07	Anticorps antivirus zika et procédés d'utilisation
EP3436476A4 (fr)	2020-04-29	Anticorps anti-ryk et leurs procédés d'utilisation
MA46290A (fr)	2019-07-31	Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA47849A (fr)	2020-01-29	Anticorps anti-gitr et leurs procédés d'utilisation
MA51552A (fr)	2021-03-24	Anticorps anti-ox40 et procédés d'utilisation
EP3491025A4 (fr)	2020-05-27	Anticorps fcrn et leurs procédés d'utilisation
EP3472200A4 (fr)	2020-04-01	Anticorps anti-myostatine et leurs procédés d'utilisation
EP3383914A4 (fr)	2019-10-30	Anticorps anti-ox40 et leurs procédés d'utilisation
EP3731867A4 (fr)	2022-04-06	Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3472316A4 (fr)	2020-01-08	Anticorps anti-c5 et leurs procédés d'utilisation
MA42971A (fr)	2018-08-15	Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation